Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
This comprehensive study explored the role of epidermal growth factor receptor (EGFR)-targeted therapies in oral cancer, focusing on emerging strategies, challenges, and future directions. The EGFR signalling pathway plays a critical role in the development and progression of oral cancer, making it...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553669621809152 |
|---|---|
| author | Vishnu Priya Veeraraghavan Shikhar Daniel Arun Kumar Dasari Kaladhar Reddy Aileni Chaitra patil Santosh R. Patil |
| author_facet | Vishnu Priya Veeraraghavan Shikhar Daniel Arun Kumar Dasari Kaladhar Reddy Aileni Chaitra patil Santosh R. Patil |
| author_sort | Vishnu Priya Veeraraghavan |
| collection | DOAJ |
| description | This comprehensive study explored the role of epidermal growth factor receptor (EGFR)-targeted therapies in oral cancer, focusing on emerging strategies, challenges, and future directions. The EGFR signalling pathway plays a critical role in the development and progression of oral cancer, making it an attractive therapeutic target. Small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) targeting EGFR have shown promise in preclinical studies and clinical trials. However, challenges, such as the development of resistance mechanisms and treatment-related toxicities, pose obstacles to their clinical utility. Future directions in EGFR-targeted therapy include the exploration of combination therapies and the identification of predictive biomarkers to optimize treatment strategies and improve patient outcomes in oral cancer. |
| format | Article |
| id | doaj-art-5b78da09e6684f49b33fd5d27e0603f0 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-5b78da09e6684f49b33fd5d27e0603f02025-01-09T06:16:51ZengElsevierOral Oncology Reports2772-90602024-09-0111100592Emerging targeted therapies in oral oncology: Focus on EGFR inhibitionVishnu Priya Veeraraghavan0Shikhar Daniel1Arun Kumar Dasari2Kaladhar Reddy Aileni3Chaitra patil4Santosh R. Patil5Centre of Molecular Medicine and Diagnostics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, TamilNadu, IndiaDepartment of Oral Medicine and Radiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, TamilNadu, IndiaDepartment of Orthodontics, SVS Institute of Dental Sciences, Mahabubnagar, Telangana, IndiaDepartment of Preventive Dentistry, College of Dentistry, Jouf University, Kingdom of Saudi ArabiaDepartment of Oral & Maxillofacial Surgery, Krishnadevaraya College of Dental Sciences & Hospital, Bangalore, IndiaDepartment of Oral Medicine and Radiology, Chhattisgarh Dental College and Research Institute, India; Corresponding author. Department of Oral Medicine and Radiology, Chhattisgarh Dental College and Research Institute, Chhattisgarh, 491441, India.This comprehensive study explored the role of epidermal growth factor receptor (EGFR)-targeted therapies in oral cancer, focusing on emerging strategies, challenges, and future directions. The EGFR signalling pathway plays a critical role in the development and progression of oral cancer, making it an attractive therapeutic target. Small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) targeting EGFR have shown promise in preclinical studies and clinical trials. However, challenges, such as the development of resistance mechanisms and treatment-related toxicities, pose obstacles to their clinical utility. Future directions in EGFR-targeted therapy include the exploration of combination therapies and the identification of predictive biomarkers to optimize treatment strategies and improve patient outcomes in oral cancer.http://www.sciencedirect.com/science/article/pii/S2772906024004382Epidermal growth factor receptor (EGFR)Oral cancerTargeted therapyTyrosine kinase inhibitors (TKIs)Monoclonal antibodies (mAbs)Combination therapy |
| spellingShingle | Vishnu Priya Veeraraghavan Shikhar Daniel Arun Kumar Dasari Kaladhar Reddy Aileni Chaitra patil Santosh R. Patil Emerging targeted therapies in oral oncology: Focus on EGFR inhibition Oral Oncology Reports Epidermal growth factor receptor (EGFR) Oral cancer Targeted therapy Tyrosine kinase inhibitors (TKIs) Monoclonal antibodies (mAbs) Combination therapy |
| title | Emerging targeted therapies in oral oncology: Focus on EGFR inhibition |
| title_full | Emerging targeted therapies in oral oncology: Focus on EGFR inhibition |
| title_fullStr | Emerging targeted therapies in oral oncology: Focus on EGFR inhibition |
| title_full_unstemmed | Emerging targeted therapies in oral oncology: Focus on EGFR inhibition |
| title_short | Emerging targeted therapies in oral oncology: Focus on EGFR inhibition |
| title_sort | emerging targeted therapies in oral oncology focus on egfr inhibition |
| topic | Epidermal growth factor receptor (EGFR) Oral cancer Targeted therapy Tyrosine kinase inhibitors (TKIs) Monoclonal antibodies (mAbs) Combination therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024004382 |
| work_keys_str_mv | AT vishnupriyaveeraraghavan emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition AT shikhardaniel emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition AT arunkumardasari emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition AT kaladharreddyaileni emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition AT chaitrapatil emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition AT santoshrpatil emergingtargetedtherapiesinoraloncologyfocusonegfrinhibition |